A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01483690 |
Recruitment Status :
Terminated
(Toxicity)
First Posted : December 1, 2011
Results First Posted : October 27, 2020
Last Update Posted : October 27, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Conditions |
Acute Lymphoblastic Leukemia Precursor B-Cell Lymphoblastic Leukemia Precursor T-Cell Lymphoblastic Leukemia |
Interventions |
Drug: Decitabine Drug: Vorinostat Drug: Vincristine Drug: Dexamethasone Drug: Mitoxantrone Drug: Pegaspargase Drug: Methotrexate |
Enrollment | 23 |
Recruitment Details | This is a pilot study where 16 patients are anticipated to be enrolled. Anticipated enrollment will take 2.5 years. |
Pre-assignment Details |
Arm/Group Title | Initial Dose Level | Modified Dose Level |
---|---|---|
![]() |
Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21. Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24 |
Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19. Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21 |
Period Title: Overall Study | ||
Started | 5 | 18 |
Completed | 3 | 13 |
Not Completed | 2 | 5 |
Reason Not Completed | ||
Adverse Event | 1 | 2 |
clinical deterioration | 1 | 0 |
Physician Decision | 0 | 2 |
exclusionary procedure | 0 | 1 |
Arm/Group Title | Initial Dose Level | Modified Dose Level | Total | |
---|---|---|---|---|
![]() |
Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21. Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24 |
Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19. Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21 |
Total of all reporting groups | |
Overall Number of Baseline Participants | 5 | 18 | 23 | |
![]() |
Total number of participants enrolled into the study.
|
|||
Age, Continuous
Median (Full Range) Unit of measure: Years |
||||
Number Analyzed | 5 participants | 18 participants | 23 participants | |
12.5
(4.9 to 14.5)
|
12.0
(1.6 to 21.4)
|
12.0
(1.6 to 21.4)
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 5 participants | 18 participants | 23 participants | |
Female |
2 40.0%
|
4 22.2%
|
6 26.1%
|
|
Male |
3 60.0%
|
14 77.8%
|
17 73.9%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 5 participants | 18 participants | 23 participants | |
Hispanic or Latino |
3 60.0%
|
9 50.0%
|
12 52.2%
|
|
Not Hispanic or Latino |
2 40.0%
|
9 50.0%
|
11 47.8%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 5 participants | 18 participants | 23 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Asian |
0 0.0%
|
1 5.6%
|
1 4.3%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
0 0.0%
|
2 11.1%
|
2 8.7%
|
|
White |
5 100.0%
|
10 55.6%
|
15 65.2%
|
|
More than one race |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Unknown or Not Reported |
0 0.0%
|
5 27.8%
|
5 21.7%
|
|
CNS Status
[1] Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 5 participants | 18 participants | 23 participants |
CNS 1 |
4 80.0%
|
14 77.8%
|
18 78.3%
|
|
CNS 2 |
1 20.0%
|
2 11.1%
|
3 13.0%
|
|
CNS 3 |
0 0.0%
|
2 11.1%
|
2 8.7%
|
|
[1]
Measure Description:
Central nervous system (CNS) disease is divided into the following: CNS 1 - no evidence of leukemia cerebral spinal fluid (CSF)(best outcome) CNS 2 - <5 WBC in CSF with blasts present CNS 3 - > or = 5 WBC in CSF with blasts present (worse outcome). |
||||
Prior hematopoietic cell transplantation (HCT)
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 5 participants | 18 participants | 23 participants |
Yes had prior HCT |
3 60.0%
|
8 44.4%
|
11 47.8%
|
|
No did not have prior HCT |
2 40.0%
|
10 55.6%
|
12 52.2%
|
|
Relapse # at enrollment
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 5 participants | 18 participants | 23 participants |
2nd Relapse |
2 40.0%
|
13 72.2%
|
15 65.2%
|
|
3rd Relapse |
1 20.0%
|
1 5.6%
|
2 8.7%
|
|
Refractory |
2 40.0%
|
4 22.2%
|
6 26.1%
|
Name/Title: | Clinical Research Coordinator, Consortia |
Organization: | Therapeutic Advancements of Childhood Leukemia and Lymphoma |
Phone: | 323-361-5312 |
EMail: | rleong@chla.usc.edu |
Responsible Party: | Therapeutic Advances in Childhood Leukemia Consortium |
ClinicalTrials.gov Identifier: | NCT01483690 |
Other Study ID Numbers: |
T2009-003 |
First Submitted: | November 29, 2011 |
First Posted: | December 1, 2011 |
Results First Submitted: | September 8, 2020 |
Results First Posted: | October 27, 2020 |
Last Update Posted: | October 27, 2020 |